Literature DB >> 29574089

Trends in phototherapy utilization among Medicare beneficiaries in the United States, 2000 to 2015.

Sally Y Tan1, Elizabeth Buzney2, Arash Mostaghimi3.   

Abstract

BACKGROUND: Phototherapy is a cost-effective treatment for many dermatoses, yet the emergence of alternative therapies such as biologics led many to think that phototherapy utilization was declining.
OBJECTIVE: To characterize national, historical phototherapy utilization and costs among Medicare beneficiaries.
METHODS: Longitudinal analysis of the Medicare Part B National Summary Data File from 2000 to 2015 for phototherapy billing codes. Geographic distribution of clinics and provider type obtained from the Medicare Provider Utilization and Payment Data for 2012 to 2015.
RESULTS: The overall volume of phototherapy services billed to Medicare from 2000 to 2015 increased by 5% annually, from 334,670 to 692,093. Ultraviolet B therapy comprised 77% of phototherapy volume, utilization of psoralen plus ultraviolet A therapy declined by 9% annually, and excimer laser services grew by 29% annually. The number of phototherapy clinics is increasing but remains concentrated in only 11% of US counties. Between 2012 and 2015, dermatologists accounted for 92% of phototherapy volume. LIMITATIONS: Commercial payers and institutional claims (hospital-based physicians) are excluded. Clinical indications for phototherapy use are not reported in this database.
CONCLUSION: Phototherapy utilization has grown, though the service mix has shifted toward ultraviolet B and laser excimer therapy and away from psoralen plus ultraviolet A therapy. Dermatologists manage most phototherapy. Uneven geographic distribution of phototherapy clinics limits access in nonurban areas, and further evaluation is needed to determine its impact on rural communities.
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Keywords:  Medicare; PUVA; excimer laser; health services research; phototherapy; psoriasis

Mesh:

Year:  2018        PMID: 29574089     DOI: 10.1016/j.jaad.2018.03.018

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

1.  Trends in the Access and Cost of Photodynamic Therapy Among Medicare Beneficiaries in the United States, 2012-2017.

Authors:  Shayan Cheraghlou; Hao Feng; Jeffrey M Cohen
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

2.  Need for Expansion of Coverage for Narrowband UVB Phototherapy in Mycosis Fungoides and Sézary Syndrome.

Authors:  Agnes Kim; Amelia Insley; Lindsey West; Heather Woodworth Goff
Journal:  Am Health Drug Benefits       Date:  2021-12

Review 3.  Phototherapy for atopic eczema.

Authors:  Annelie H Musters; Soudeh Mashayekhi; Jane Harvey; Emma Axon; Stephanie J Lax; Carsten Flohr; Aaron M Drucker; Louise Gerbens; John Ferguson; Sally Ibbotson; Robert S Dawe; Floor Garritsen; Marijke Brouwer; Jacqueline Limpens; Laura E Prescott; Robert J Boyle; Phyllis I Spuls
Journal:  Cochrane Database Syst Rev       Date:  2021-10-28

Review 4.  Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications.

Authors:  Patrick J McCullough; William P McCullough; Douglas Lehrer; Jeffrey B Travers; Steven J Repas
Journal:  Nutrients       Date:  2021-04-29       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.